SCHEMBL21705044

SCHEMBL21705044

O=C(c1cccc(-c2nc3ccccc3[nH]2)c1)N1CCN(C(=O)c2cccc(-c3nc4ccccc4[nH]3)n2)CC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LANCL2 Q9NS86 1/20 0.79
KDM4E B2RXH2 5/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
ALDH1A1 P00352 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
HPGD P15428 3/20 0.58
ATR Q13535 3/20 0.55
MGLL Q99685 2/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
COMT P21964 1/20 0.49
MMP8 P22894 1/20 0.49
MMP13 P45452 1/20 0.49
HTR2B P41595 3/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17706589 0.90 KDM4E (0.70) LANCL2KDM4ENPC1RAB9AALDH1A1
Omilancor SCHEMBL17706588 0.89 LANCL2 (1.00) LANCL2KDM4ENPC1RAB9AALDH1A1
Omilancor SCHEMBL29349469 0.89 LANCL2 (1.00) LANCL2KDM4ENPC1RAB9AALDH1A1
SCHEMBL21043129 0.86 LANCL2 (0.93) LANCL2KDM4ENPC1RAB9AALDH1A1
SCHEMBL25310542 0.84 LANCL2 (0.76) LANCL2KDM4ENPC1RAB9AALDH1A1
SCHEMBL18805072 0.83 LANCL2 (0.88) LANCL2KDM4ENPC1RAB9AALDH1A1
SCHEMBL17705594 0.83 LANCL2 (0.88) LANCL2KDM4ENPC1RAB9AALDH1A1
SCHEMBL25877324 0.82 LANCL2 (0.59) LANCL2KDM4ENPC1RAB9AALDH1A1
SCHEMBL29466338 0.82 LANCL2 (0.86) LANCL2KDM4ENPC1RAB9AALDH1A1
SCHEMBL25877375 0.82 LANCL2 (0.86) LANCL2KDM4ENPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10682349-B2 Lanthionine synthetase C-like 2-based therapeutics LANDOS BIOPHARMA, INC. (US) 2020-06-16 US disclosed
US-20200046694-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS LANDOS BIOPHARMA, INC. (US) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10682349-B2 Lanthionine synthetase C-like 2-based therapeutics LANCL2, CBS, LCP2 LANCL2 1/4885KDM4E 3829/4885NPC1 1574/4885
US-20200046694-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS LANCL2, CBS, LCP2 LANCL2 1/4885KDM4E 3829/4885NPC1 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.